Tuberculin testing before BCG vaccinationBMJ 2003; 327 doi: https://doi.org/10.1136/bmj.327.7409.243 (Published 31 July 2003) Cite this as: BMJ 2003;327:243
- Graham H Bothamley, lead physician for tuberculosis,
- Ed Cooper, consultant paediatrician,
- Delane Shingadia, senior lecturer in paediatrics,
- Alex Mellanby, consultant in communicable disease control
- North East London Tuberculosis Network, Homerton University Hospital, London E9 6SR
- Partnership for Child Development, Department of Infectious Disease Epidemiology, St Mary's Campus, Imperial College, London W2 1PF
- Queen Mary College Westfield, London E1 4NS
- Health Protection Agency, London E1 1RD
May not be necessary
BCG vaccination is effective against forms of tuberculosis that occur commonly in childhood that have a high morbidity and mortality, such as tuberculous meningitis.1 2 Current guidelines for the United Kingdom recommend tuberculin skin testing before BCG vaccination for all children older than 3 months.3 The evidence base for this recommendation is unclear—no randomised controlled trials have been conducted to compare outcome of BCG vaccination with and without prior tuberculin skin testing, and the resulting two or three stage procedure seriously compromises uptake.
The BCG vaccine was not available in the United Kingdom from 9 August 2002—when all stocks from the monopoly supplier, Evans Vaccines, were declared potentially ineffective by the Medicines Control Agency and the Department of Health—until supplies from Denmark's State Serum Institute became accessible during December 2002. The currently available BCG vaccine is for intradermal use only. From November 1998 to July 2001 a similar loss of supply of percutaneous BCG vaccine, which is …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial